| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|
| May 2, 2016 D Curtis Mathes Corp File 021-262389 | $0 | $25,000 | $25,000 Finder's fee paid to affiliate of company officer. | None listed on this filing | EDGAR ↗ |
| Aug 5, 2014 D/A NORTHSIGHT CAPITAL, INC. File 021-213763 | $0 | $150,000 (est.) | $450,000 (est.) Assumes the maximum amount will be raised and that the proceeds will be expended over approximately 12 months. Consists of President's salary ($25,000 per month), rent ($3,000 per month)and consulting fees (9,500 per month). | None listed on this filing | EDGAR ↗ |
| Jul 17, 2014 D/A NORTHSIGHT CAPITAL, INC. File 021-221224 | $0 | $0 | $0 (est.) No cash proceeds are being received by the Issuer. | None listed on this filing | EDGAR ↗ |
| May 5, 2014 D NORTHSIGHT CAPITAL, INC. File 021-216778 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 15, 2014 D NORTHSIGHT CAPITAL, INC. File 021-215639 | $0 | $0 | $0 (est.) No cash proceeds were received as the shares were issued in cancellation of outstanding shares of the issuer's sister company. | None listed on this filing | EDGAR ↗ |
| Mar 28, 2014 D Zivo Bioscience, Inc. File 021-214491 | $0 | $0 | $25,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Dec 24, 2013 D Zivo Bioscience, Inc. File 021-208712 | $0 | $0 | $50,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Dec 23, 2013 D Zivo Bioscience, Inc. File 021-208637 | $0 | $0 | $125,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Aug 26, 2013 D Zivo Bioscience, Inc. File 021-201885 | $0 | $0 | $25,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Aug 12, 2013 D Zivo Bioscience, Inc. File 021-201145 | $0 | $0 | $50,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Jan 7, 2013 D Zivo Bioscience, Inc. File 021-189657 | $0 | $0 | $20,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Dec 27, 2012 D Zivo Bioscience, Inc. File 021-188989 | $0 | $0 | $20,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Dec 26, 2012 D Zivo Bioscience, Inc. File 021-188957 | $0 | $0 | $50,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| Jul 27, 2012 D Zivo Bioscience, Inc. File 021-181859 | $0 | $0 | $30,000 (est.) | None listed on this filing | EDGAR ↗ |
| Jul 27, 2012 D Zivo Bioscience, Inc. File 021-181860 | $0 | $0 | $30,000 (est.) Proceeds will be used for general working capital, which may include the payment of compensation to executive officers or directors. | None listed on this filing | EDGAR ↗ |
| May 24, 2012 D Zivo Bioscience, Inc. File 021-178753 | $0 | $0 | $20,000 (est.) Assumes the full $300,000 is raised and is used over a 2 1/2 month period. The $20,000 in payments consists of compensation to officers. | None listed on this filing | EDGAR ↗ |
| May 14, 2012 D/A Zivo Bioscience, Inc. File 021-169909 | $0 | $0 | $160,000 (est.) "Assumes the full $2,000,000 is raised and is used over a five month period. The aggregate $110,000 in payments consists of compensation to officers of $85,000 and payment of rent to ""promoters"" of $75,000." | None listed on this filing | EDGAR ↗ |
| Apr 10, 2012 D/A Zivo Bioscience, Inc. File 021-169839 | $0 | $42,600 (est.) | $120,000 (est.) Assumes net proceeds from $500K offering will be expended over three months. Comprised of $30K in fees to the contract CFO, $45K in salary payments to the CEO and $45K in rent payments to the Company's founder (promoter). | None listed on this filing | EDGAR ↗ |
| Nov 14, 2011 D Zivo Bioscience, Inc. File 021-168649 | $0 | $2,500 (est.) | $200,000 (est.) is the aggregate amount expected to be paid out over 6 months to executive officers (salary) and promoters (rent) | None listed on this filing | EDGAR ↗ |
| Sep 2, 2011 D/A Zivo Bioscience, Inc. File 021-155241 | $0 | $2,500 (est.) | $175,000 (est.) $175,000 is the aggregate amount expected to be paid out over 7 months to executive officers (salary) and promoters (rent) | None listed on this filing | EDGAR ↗ |
| Jun 1, 2011 D/A Zivo Bioscience, Inc. File 021-78915 | $0 | $143,000 (est.) | $550,000 (est.) $550,000 is the aggregate amount expected to be paid out over 8 months to executive officers (salary) and promoters (rent and licensing and contract modification fees) | None listed on this filing | EDGAR ↗ |
| Oct 26, 2010 D/A KUBOO, INC. File 021-147610 | $0 | $200,000 (est.) | $342,000 (est.) Assumes that the proceeds will be expended over a one year period. Comprised of $42,000 in rent and $300,000 for business advisory services. | None listed on this filing | EDGAR ↗ |
| Apr 28, 2010 D Zivo Bioscience, Inc. File 021-141203 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |